Alomnertinib Mesilate — Competitive Intelligence Brief

Alomnertinib Mesilate (Alomnertinib Mesilate) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Third-generation EGFR tyrosine kinase inhibitor. Area: Oncology.

phase 2 Third-generation EGFR tyrosine kinase inhibitor EGFR (Epidermal Growth Factor Receptor), particularly mutant forms including T790M Oncology Small molecule

Target snapshot

Alomnertinib Mesilate (Alomnertinib Mesilate) — Shanghai Hengrui Pharmaceutical Co., Ltd.. Alomnertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alomnertinib Mesilate TARGET	Alomnertinib Mesilate	Shanghai Hengrui Pharmaceutical Co., Ltd.	phase 2	Third-generation EGFR tyrosine kinase inhibitor	EGFR (Epidermal Growth Factor Receptor), particularly mutant forms including T790M
ASKC202+ Limertinib	ASKC202+ Limertinib	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	phase 3	Bispecific antibody + third-generation EGFR tyrosine kinase inhibitor combination	EGFR (epidermal growth factor receptor) and c-MET (mesenchymal-epithelial transition factor)
SHR-A2009 ; Aumolertinib	SHR-A2009 ; Aumolertinib	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (Epidermal Growth Factor Receptor), particularly mutant forms including T790M
AZD9291	AZD9291	Soroka University Medical Center	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (Epidermal Growth Factor Receptor)
Furmonertinib Mesilate Tablets	Furmonertinib Mesilate Tablets	Allist Pharmaceuticals, Inc.	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)
Firmonertinib Mesilate Tablets	Firmonertinib Mesilate Tablets	Allist Pharmaceuticals, Inc.	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (Epidermal Growth Factor Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Third-generation EGFR tyrosine kinase inhibitor class)

1. Allist Pharmaceuticals, Inc. · 2 drugs in this class
2. Shanghai Hengrui Pharmaceutical Co., Ltd. · 1 drug in this class
3. Soroka University Medical Center · 1 drug in this class
4. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class